{"filings":[{"id":81721,"accession_number":"0001193125-26-223071","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-05-14T14:22:48+00:00","items":["5.07","9.01"],"status":"ready","headline":"Mereo BioPharma shareholders approve all 11 resolutions at 2026 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["436,766,255 ordinary shares represented at the May 14, 2026 AGM.","Directors Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz re-elected with >93% support each.","Directors' remuneration policy approved with 91.74% of votes for.","Authorization to allot shares up to £3,591,354.73 passed with 80.54% for, valid until June 30, 2029.","All resolutions including auditor reappointment and advisory say-on-pay passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":23163,"accession_number":"0001193125-26-218290","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K/A","filed_at":"2026-05-12T12:56:29+00:00","items":["2.02","2.01","9.01"],"status":"ready","headline":"Mereo BioPharma Q1 net loss $6.7M; setrusumab Phase 3 fails primary endpoint, regulator engagement begun","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.7M in Q1 2026 vs $12.9M in Q1 2025; cash and equivalents $36.2M as of March 31, 2026.","Setrusumab Phase 3 studies in OI did not meet primary fracture-rate endpoints; high significance on BMD, vertebral fracture reduction, and PROs.","Mereo and partner Ultragenyx initiated regulatory discussions for pediatric OI path; no approved therapies exist.","Alvelestat partnership discussions active; single Phase 3 trial of ~220 patients with SGRQ (US) and lung density (EU) endpoints planned."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22481,"accession_number":"0001193125-26-218192","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-05-12T11:33:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q1 2026 net loss $6.7M; setrusumab regulatory dialogue initiated for pediatric OI","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.7M vs $12.9M YoY; cash $36.2M as of March 31, expected runway into mid-2027.","Setrusumab Phase 3 studies missed primary fracture endpoint but achieved significant bone mineral density and PRO improvements; regulatory engagement for pediatric OI started.","Alvelestat partnership discussions ongoing; single Phase 3 trial (~220 patients) could start within 6 months of deal.","Vantictumab Phase 2 in osteopetrosis expected H2 2026 by partner āshibio; Mereo retains European rights.","R&D expenses $4.7M (+$0.8M YoY) driven by setrusumab manufacturing costs; G&A $4.0M (-$3.3M) due to ADR reimbursement and savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107723,"accession_number":"0001193125-26-127253","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Annalisa Jenkins not seeking re-election to Mereo BioPharma board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Annalisa Jenkins will not stand for re-election at the 2026 AGM scheduled for May 14, 2026.","Her decision did not result from any disagreement with the Company or Board on operations, policies, or practices.","She will continue to serve as a director until her term expires immediately prior to the 2026 AGM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107722,"accession_number":"0001193125-26-115211","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma FY2025 net loss $41.9M; setrusumab Phase 3 studies miss primary endpoints, show BMD gains","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $41.0M as of Dec 31, 2025; expected runway into mid-2027 (from $69.8M end 2024).","Setrusumab Phase 3 Orbit & Cosmic missed primary endpoint (annualized clinical fracture rate) but achieved high statistical significance on BMD improvement.","Setrusumab showed vertebral fracture reductions and statistically significant PRO improvements in pain/daily activity in pediatric patients.","Alvelestat site feasibility for Phase 3 in AATD-LD complete; partnering discussions ongoing; Phase 2b in bronchiectasis designed.","Vantictumab outlicensed to āshibio; Phase 2 in osteopetrosis planned H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107721,"accession_number":"0001193125-26-054787","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Mereo Biopharma receives Nasdaq bid price deficiency notice; compliance period through Aug 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received letter on Feb 17, 2026 re: ADS closing bid price below $1.00 for 30 consecutive business days.","180-day compliance period until August 17, 2026 to regain minimum bid price requirement.","To regain compliance, bid price must close at $1.00+ for at least 10 consecutive business days.","If not compliant by Aug 17, may be eligible for additional 180-day grace period subject to other Nasdaq standards.","ADSs continue trading under MREO; company states business operations unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107720,"accession_number":"0001193125-26-009829","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Mereo BioPharma reports setrusumab Phase 3 miss; extends cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents $41M as of Dec 31, 2025; reduced pre-commercial spend extends runway to mid-2027.","Setrusumab Phase 3 Orbit/Cosmic missed primary fracture-rate endpoints; BMD secondary endpoint met (p<0.001).","Alvelestat Phase 3 plan: single 220-patient trial over 18 months; partnering discussions ongoing.","Vantictumab out-licensed to ashibio for ADO2; Phase 2 expected 2H 2026; Mereo retains EU rights.","No approved OI therapies in US/EU except Italy's neridronate; high unmet need remains."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124089,"accession_number":"0001193125-25-332520","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Mereo setrusumab Phase 3 trials miss primary fracture endpoints; BMD improvements seen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Neither ORBIT (placebo) nor COSMIC (bisphosphonate) achieved statistical significance on annualized clinical fracture rate.","Both studies met secondary endpoint of bone mineral density (BMD) improvements with strong statistical significance.","Cash balance $48.7M at Q3 2025; company reducing pre-commercial and manufacturing costs.","Additional analyses underway; management cites low placebo fracture rate in ORBIT.","Continued partnering discussions for alvelestat; pipeline programs with partners remain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124088,"accession_number":"0001193125-25-274319","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q3 2025 net loss narrows to $7.0M; cash $48.7M; setrusumab data expected year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.0M in Q3 2025 vs $15.0M in Q3 2024; operating loss of $10.0M.","Cash and cash equivalents $48.7M as of Sep 30, 2025 (down from $69.8M Dec 31, 2024).","R&D expenses rose to $4.3M (up $1.1M YoY) driven by setrusumab manufacturing and alvelestat Phase 3 prep.","Phase 3 Orbit (p<0.039) and Cosmic (p<0.05) data for setrusumab in OI expected around end of 2025.","Partnering discussions for alvelestat ongoing; vantictumab license to āshibio with retained EU rights."],"consensus_eps_estimate":-0.0248,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140756,"accession_number":"0000950170-25-106924","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q2 net loss $14.6M; setrusumab Phase 3 data due year-end 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.6M in Q2 2025 vs $12.3M in Q2 2024; cash $56.1M as of June 30, 2025.","Phase 3 Orbit and Cosmic studies of setrusumab in OI on track for final analysis around year-end 2025.","DMC interim analysis in July 2025 confirmed acceptable safety for setrusumab; study continues to final analysis.","R&D expenses $5.4M (+$0.4M YoY) driven by setrusumab manufacturing; G&A down $2.4M to $5.5M.","Alvelestat partnering discussions ongoing; cash expected to fund operations into 2027."],"consensus_eps_estimate":-0.0167,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140755,"accession_number":"0000950170-25-094921","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mereo BioPharma and Ultragenyx Provide Update on Phase 3 Orbit and Cosmic Studies of UX143 in Osteogenesis Imperfecta","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["The Phase 3 Orbit study final analysis is expected around end of 2025, with a threshold of p<0.04.","DMC informed Ultragenyx that UX143 has an acceptable safety profile and study should continue to final analysis.","Safety in the younger patient population (Cosmic study) is consistent with other studies; no interim analysis of Cosmic data.","Final analyses will occur after patients have been on therapy for at least 18 months; threshold for Cosmic is p<0.05."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158496,"accession_number":"0000950170-25-071485","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Mereo BioPharma 2025 AGM: all resolutions pass; board elects annual say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Resolutions 1-5 and 7-9 passed with over 85% of votes cast.","Resolution 6 (advisory vote on frequency of exec comp) received 48% for 1-year, 46% for 3-year; board chooses annual frequency until 2031.","Re-elected directors Deepika Pakianathan, Pierre Jacquet, Michael Wyzga each won >85% support.","PricewaterhouseCoopers re-appointed as auditor with 99.58% of votes cast.","Total 624,188,662 ordinary shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158495,"accession_number":"0000950170-25-069811","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q1 net loss $12.9M; setrusumab Phase 3 Orbit on track for mid-year readout","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $12.9M (Q1 2024: $9.0M) on operating loss of $11.2M.","Cash and equivalents $62.5M at March 31, 2025, down from $69.8M at year-end; runway into 2027.","R&D expenses $3.9M, flat YoY; setrusumab costs increased $1.3M offset by alvelestat decrease.","Phase 3 Orbit study of setrusumab in OI on track for second interim mid-2025 or final Q4 2025.","Alvelestat granted EU orphan designation for alpha-1 antitrypsin deficiency lung disease."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176879,"accession_number":"0000950170-25-044783","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma FY2024 net loss $43.3M; cash $69.8M funds operations into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $43.3M in FY2024 vs $29.5M in FY2023; R&D expenses rose $3.5M to $20.9M driven by alvelestat and setrusumab.","Cash and equivalents of $69.8M as of Dec 31, 2024; expected to fund operations into 2027.","Phase 3 Orbit study of setrusumab in OI progressing; second interim analysis expected mid-2025, final Q4 2025.","Alvelestat granted EU Orphan Designation for AATD-LD in Q1 2025; partnering discussions ongoing.","Pre-commercial activities for setrusumab in Europe advancing with NICE and GBA scientific advice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176878,"accession_number":"0000950170-25-004523","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Mereo BioPharma: setrusumab Phase 3 Orbit 2nd interim analysis mid-2025; alvelestat gets positive EMA orphan opinion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 Orbit study of setrusumab in OI progressing to second interim analysis expected mid-2025; final analysis possible Q4 2025.","Alvelestat receives positive EMA COMP opinion for Orphan Designation; European Commission final decision expected Q1 2025.","Cash runway reaffirmed into 2027, funding through multiple key inflection points including setrusumab milestones.","Cosmic study in OI patients aged 2 to <7 years continuing; data will be evaluated with Orbit analyses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193679,"accession_number":"0000950170-24-124598","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q3 net loss $15M; cash $80.5M; amends AstraZeneca deal with $114.3M milestone potential","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Amended AstraZeneca license agreement modifies development milestones; potential future payments up to $114.3M in cash and ADSs; issued 2.04M shares and paid $0.5M.","Q3 net loss $15.0M vs $6.5M YoY, driven by $6.4M foreign exchange loss; R&D down 12% to $3.2M.","Cash $80.5M as of Sep 30, 2024 (up from $57.4M Dec 2023); expected to fund operations into 2027.","Setrusumab received FDA Breakthrough Therapy designation for osteogenesis imperfecta; Phase 3 topline data expected 2025.","Alvelestat remains on track to be Phase 3-ready by end of 2024; partnership discussions ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209991,"accession_number":"0001193125-24-199430","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q2 net loss $12.3M; setrusumab studies fully enrolled, fracture rate cut 67%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $87.4M as of June 30, 2024, including $50M June offering; runway into 2027.","Net loss $12.3M in Q2 2024 vs $1.8M in Q2 2023, driven by $9.0M milestone payment in prior year.","Phase 3 Orbit and Cosmic studies of setrusumab in OI fully enrolled by April 30, 2024.","Setrusumab reduced median annualized fracture rate by 67% (p=0.0014) over 16 months mean treatment.","R&D expenses $4.9M (+33% YoY); G&A expenses $7.9M (+$5.2M) on pre-commercial activity."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228196,"accession_number":"0001193125-24-161662","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Mereo BioPharma prices $50M registered direct offering of 12.5M ADS at $3.99/ADS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $50M from 12,531,300 ADS at $3.99 each; net proceeds ~$45.9M after expenses.","Underwriters: Jefferies, Leerink Partners, and Cantor Fitzgerald acting as joint book-runners.","New investors include Frazier Life Sciences, Deerfield Management, and Perceptive Advisors; existing holder participation.","Net proceeds to fund setrusumab program (supply and pre-launch in Europe) and general corporate purposes.","Offering expected to close on June 17, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228195,"accession_number":"0001193125-24-159393","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Setrusumab Phase 2 data: 67% fracture rate reduction in OI at 14 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median annualized fracture rate reduced 67% to 0.00 (p=0.0014, n=24) vs pre-treatment 0.72.","Lumbar spine BMD increased mean 22% at 12 months (p<0.0001, n=19); Z-score improved +1.25 (p<0.0001, n=18).","No treatment-related serious adverse events or hypersensitivity reactions reported.","Phase 3 Orbit (158 patients) and Cosmic (69 patients) studies fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228194,"accession_number":"0001193125-24-145983","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"All seven proposals approved at Mereo BioPharma 2024 AGM; director re-elections pass with >91% support","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual report adopted with 99.66% of votes cast in favor; PwC reappointed as auditor (99.60% support).","Dr. Denise Scots-Knight re-elected as director (91.13% for), Dr. Jeremy Bender re-elected (92.46% for), Dr. Anders Ekblom re-elected (94.12% for).","Directors' remuneration report approved with 98.63% of votes cast in favor.","All votes based on 536,018,312 ordinary shares represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228193,"accession_number":"0001193125-24-139366","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma Q1 net loss $9.0M, cash $48.7M; setrusumab enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.0M in Q1 2024 vs $12.1M in Q1 2023; operating loss $9.9M.","Cash and equivalents $48.7M as of March 31, 2024, down from $57.4M at Dec 31, 2023.","Phase 3 Orbit study (setrusumab) fully enrolled (158 patients); Cosmic enrolled 69 patients.","Alvelestat SGRQ validation completed; Phase 3 protocol to be submitted to FDA in H1 2024.","Cash guidance unchanged: funds operations into 2026; no alvelestat partnership upfront included."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228192,"accession_number":"0001193125-24-095508","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Mereo BioPharma extends cooperation with Rubric Capital; Justin Roberts to remain on board through 2025 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension letter dated April 15, 2024 waives resignation requirement for director Justin Roberts after 2024 AGM.","Termination date of Cooperation Agreement extended to immediately after the 2025 annual shareholder meeting.","Cooperation Agreement originally dated October 28, 2022 between Mereo and Rubric Capital Management L.P."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246946,"accession_number":"0001193125-24-078800","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.","Cash $57.4M; net cash burn Q4 2023 $6.7M; expected runway into 2026 supporting current plans.","Setrusumab Orbit (Phase 2/3) enrollment completes Q1 2024; Cosmic (Phase 3) H1 2024, by partner Ultragenyx.","Alvelestat Phase 3 plan with partner around end 2024; FDA aligned on SGRQ primary endpoint.","Leflutrozole licensed to ReproNovo for up to $64.25M milestones plus tiered mid-single digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246945,"accession_number":"0001193125-24-003868","cik":1719714,"company_name":"Mereo BioPharma Group plc","ticker":"MREO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Setrusumab OI trials on track; alvelestat FDA alignment; leflutrozole licensed for up to $64.25M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Setrusumab: Phase 3 Orbit study (195 patients) expected full enrollment around end Q1 2024; Cosmic study (~65 patients) expected full enrollment 1H 2024.","Phase 2 data showed 67% reduction in annualized fracture rate; additional data expected 2024.","Alvelestat: FDA aligned on Phase 3 design with SGRQ Total Score as primary endpoint; could support full U.S. approval.","Leflutrozole: global license deal with ReproNovo; Mereo received upfront payment and up to $64.25M in milestones plus tiered royalties.","Cash runway guidance reaffirmed: existing cash expected to fund operations into 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":52465703.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}